Community reports — not medical advice
These are community-reported observations, not clinical recommendations, and have not been verified by medical professionals. Do not use them as the basis for any health decisions.
Notable threads from Reddit and peptide forums, grouped by theme. Filter by category, sentiment, or peptide to find what is relevant to you.
How the community is running peptides: doses, stacks, cycles, routes.
A user solicits experiences from people running retatrutide and tirzepatide together, reflecting community interest in combining or transitioning between the two incretin agents; the thread is a question to peers, with no comments pulled to capture responses.
A user asks whether others have combined tirzepatide with CJC-1295 DAC, soliciting community experience on running a GLP-1/GIP agonist alongside a growth-hormone-releasing-hormone analog in the same protocol.
A user-profile post asking whether to choose Mounjaro (tirzepatide) or retatrutide, a comparison question commonly raised by people deciding between the two incretin-based compounds.
A 37-year-old man shares a before-and-now progress post, notes he is about to start TRT, and asks whether tirzepatide or retatrutide is the better fit for reducing abdominal and visceral fat while preserving muscle.
A 37-year-old man sharing progress photos and about to start testosterone therapy asks whether tirzepatide or retatrutide is the better fit for targeting abdominal and visceral fat while keeping muscle mass. The thread compares the two incretin agonists for body-composition goals.
Community discussion of studies and data.
A historical overview tracing peptide therapeutics from the discovery of insulin through to the current GLP-1 receptor agonist era, contextualizing modern agents such as semaglutide and tirzepatide within a century of drug development.
FDA, compounding, and market/legal news.
A community explainer on Eli Lilly's federal litigation over compounded and modified versions of its incretin products, framed around a dispute reportedly hinging on a two-amino-acid difference; the thread synthesizes the legal stakes for the gray-market tirzepatide ecosystem as community commentary, not legal analysis.
Other community conversation.
A TRT-community poll asking whether members would have chosen tirzepatide or retatrutide over testosterone therapy if the incretin compounds had been available first, probing overlap between weight loss and hormonal goals.